ACP
DSGN icon

Acuta Capital Partners’s Design Therapeutics DSGN Stock Holding History

Acuta Capital Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09M Buy
282,564
+136,664
+94% +$1.7M 2.85% 13
2026
Q1 		$1.55M Sell
145,900
-5,006
-3% -$50.7K 1.1% 20
2025
Q4 		$1.42M Buy
+150,906
New +$1.18M 0.96% 18

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acuta Capital Partners's DSGN Position: Q2 2026 in Review

Acuta Capital Partners increased its Design Therapeutics (DSGN) stake by 94% in Q2 2026, buying an estimated $1.7M and bringing the position to 282,564 shares worth $4.09M. The position accounts for 2.85% of the portfolio, ranked #13.

Acuta Capital Partners first reported a position in DSGN in Q4 2025 and has held it in 3 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Acuta Capital Partners held 282,564 shares of Design Therapeutics worth $4.09M as of Q2 2026.
  • Acuta Capital Partners bought 136,664 Design Therapeutics shares in Q2 2026, an estimated $1.7M.
  • Design Therapeutics made up 2.85% of Acuta Capital Partners's portfolio in Q2 2026, its #13 holding.
  • Acuta Capital Partners first reported a position in Design Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.